Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis IncfiledCriticalExelixis Inc
Priority to HN2009003001ApriorityCriticalpatent/HN2009003001A/en
Publication of HN2009003001ApublicationCriticalpatent/HN2009003001A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
LA PRESENTE INVENCION PROPORCION METODOS DE TRATAR CANCER POR LA ADMINISTRACION DE UN COMPUESTO DE FORMULA 1, OPCIONALMENTE EN FORMA DE SUS SALES FARMACEUTICAS ACEPTABLE, SUS SOLVATOS Y/O HIDRATOS, EN COMBINACION CON OTROS TRATAMIENTOS DE CANCER.THIS INVENTION PROVIDES METHODS OF TREATING CANCER FOR THE ADMINISTRATION OF A FORMULA COMPOUND 1, OPTIONALLY IN THE FORM OF ITS ACCEPTABLE PHARMACEUTICAL SALTS, ITS SOLVATES AND / OR HYDRATS, IN COMBINATION WITH OTHER CANCER TREATMENTS.
HN2009003001A2009-10-092009-10-09
USE OF PI3K-ALFA QUINAXOLINE INHIBITED COMPOUNDS FOR CANCER TREATMENT
HN2009003001A
(en)
Compounds derived from pharmaceutically acceptable 2,4-diaminoquinazolines, salts or solvates; pharmaceutical composition comprising them; and use in the treatment of a disorder involving the modulation of tlr7 and / or tlr8.
Compounds derived from n- (pyridin-3-yl) -1,3-thiazole-5-amino-4-carboxamide, pim kinase inhibitors; pharmaceutical composition; and use for the treatment of cancer.